Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 37.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 8, 2025

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.

GlobeNewsWire • Nov 26, 2025

Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High?

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 46.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Nov 21, 2025

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Tango Therapeutics, Inc. is initiated with a Buy rating due to strong progress with its lead PRMT5 inhibitor, vopimetostat, for MTAP-deleted cancers. TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications.

Seeking Alpha • Nov 21, 2025

Tango Therapeutics, Inc. (TNGX) Tops Q3 Earnings and Revenue Estimates

Tango Therapeutics, Inc. (TNGX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.27 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025.

The Motley Fool • Oct 31, 2025

Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 52.2% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Oct 31, 2025

Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why

Tango Therapeutics (TNGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Oct 27, 2025

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Benzinga • Oct 23, 2025

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Tango Therapeutics, Inc. (NASDAQ:TNGX ) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers October 23, 2025 8:30 AM EDT Company Participants Elizabeth Hickin - VP of IR & Corporate Communications Barbara Weber - President, CEO & Director Adam Crystal - President of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Peter Lawson - Barclays Bank PLC, Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Presentation Operator Good day.

Seeking Alpha • Oct 23, 2025